SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.17+3.9%Dec 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9144)9/16/2003 6:28:46 PM
From: BulbaMan  Read Replies (2) of 52153
 
What seems weird to me is that Genta/Aventis lead off their press release announcing the results with the confusing data for the full 771 patients (which did not reach significance).
As the companies explained in the CC, melanoma patients (in the disease stage enrolled in the trial) survive, on average, 6-8 months on chemo alone. So comparing the chemo-only group to the chemo-Genasense group for patients enrolled less than 6-8 months makes no sense, as the benefits of Genasense were never expected to show up until after 6-8 months elapsed.
Therefore, it's difficult to understand why Genta/Aventis highlighted a statistic which included data for many patients enrolled in the trial for less than the 6-8 month period. If they felt they needed to present all the data they could have simply given the separate survival numbers for the 291 patients in the trial for less than 12 months and clearly explained in the press release why they expected, once these patients reached the 12 month endpoint, their survival data would end up being the same as for the 480 patients already beyond the 12 month endpoint.
Anyone have a clue as to why Genta/Aventis highlighted the confusing, combined data for all 771 patients?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News